HCW Biologics Signs Agreement With Akron Biotech To Commercialize HCW11-006 To Use As Reagent For New Method Of Human CAR-T Cells Production To Treat Cancer
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune
HCW Biologics made a deal to help another company use their tool to make CAR-T cells—a special type of medicine that fights cancer. This shows HCW's science might be useful to others, which could help the company grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.